EFPIA - NEWSLETTER

EFPIA Newsletter 24 November 2022

Podcasts

21 November 2022 What would be the impact of a TRIPS waiver extension?

Industry has shown its commitment to work with partners in order to ensure that vaccines and therapies reach patients...

Blogs

24 November 2022 How to improve patient access to novel antibiotics in Europe: Recommendations for policies...

A new report seeks to highlight the significant barriers existing at the national level - related to value-assessment...

23 November 2022 What would be the impact of a waiver extension

Waiving IP would not only attempt to solve a problem that does not exist. It would send a clear message to companies...

22 November 2022 Medicine shortages: EFPIA proposals for action

9 concrete proposals underpinned by 5 principles to help protect patients across Europe from the impact of shortages...

22 November 2022 How research pharmaceutical companies are contributing towards tackling global warming

Understanding the relationship between people, health and the environment is critical to ensuring the pharmaceutical...

How can we reverse Europe's declining trend in medical innovation?

Dhaval Patel, Executive Vice President and Chief Scientific Officer, UCB, and Nathalie Moll, Director General, EFPIA, presented the key findings of the "Factors affecting the location of biopharmaceutical investments" report at the 2022 European Business Summit.

Watch the recording of the exclusive interview here.

Events

28 NOV 2022

DIA Health Technology Assessment (HTA) Forum Brussels, Belgium Learn more →

08 DEC 2022

European Health Summit 2022 Egmont Palace, Brussels

Join us on 8th December!

Learn more →

12 DEC 2022

How can we reduce premature and preventable deaths caused by cardiovascular diseases... Brussels Learn more →

09 FEB 2023

ACCELERATE 2023 Annual Conference Brussels & online

All sessions, including Breakout Sessions, will be available for both in-person and online participants.

Learn more →

The Power of Innovation

Innovative treatments for Rheumatoid Arthritis reduce pain and improve quality of life. For patients, it means the chance to go to work: 132 million working days are gained per year through reducing absenteeism.

What we are reading

Europe can and must remain a globally competitive region for medical innovation 24 November 2022 (Gold News)

As WTO Considers Patent Waiver on COVID Treatments, Some Say it is Too Late 24 November 2022 (Health Policy Watch)

EU health data space impossible without trust, Commissioner says 16 November 2022 (Euractiv)

About the EFPIA newsletter

The European Federation of Pharmaceutical Industries and Associations (EFPIA) represents the pharmaceutical industry operating in Europe. Through its direct membership of 36 national associations and 39 leading pharmaceutical companies, EFPIA is the voice on the EU scene of 1,900 companies committed to researching, developing and bringing to patients new medicines that will improve health and the quality of life around the world.

Tel: +32 (0)2 626 25 55
Communications@efpia.eu

▶